The protease thrombin is required for normal hemostasis and pathologic thrombogenesis. Since the mechanism of coagulation factor XI (FXI)-dependent thrombus growth remains unclear, we investigated the contribution of FXI to thrombus formation in a primate thrombosis model. Pre-treatment of baboons with a novel antihuman FXI monoclonal antibody (aXIMab -2 mg/kg), inhibited plasma FXI by ≥ 99% for 10 days, and suppressed thrombin-antithrombin (TAT) complex and β-thromboglobulin (βTG) formation measured immediately downstream from thrombi forming within collagen-coated vascular grafts. FXI inhibition with aXIMab limited platelet and fibrin deposition in 4 mm diameter grafts without an apparent increase in D-dimer release from thrombi, and prevented the occlusion of 2 mm diameter grafts without affecting template bleeding times. In comparison, pre-treatment with aspirin (32 mg/kg) prolonged bleeding times but failed to prevent graft occlusion, supporting the concept that FXI blockade may offer therapeutic advantages over other antithrombotic agents in terms of bleeding complications. In whole blood, aXIMab prevented fibrin formation in a collagen-coated flow chamber, independent of factor XII and factor VII. These data suggest that endogenous FXI contributes to arterial thrombus propagation through a striking amplification of thrombin generation at the thrombus luminal surface.
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Introduction
Blood coagulation during hemostasis is initiated by the tissue factor (TF)/factor VIIa complex (the extrinsic pathway) that activates factors IX and X, and ultimately produces thrombin at sites of vascular injury. 1 In thrombosis, intravascular blood coagulation may also be initiated by the extrinsic pathway. 2, 3 However, impairment of the TF/factor VIIa pathway does not provide full protection from thrombosis, since symptomatic factor VII deficient subjects can develop concurrent thrombosis and severe bleeding. 4 The functions of the contact proteins (factor XI, factor XII, prekallikrein and high-molecularweight kininogen) in hemostasis are less clear. The physiological role of factor XI (FXI) has been difficult to determine because of the variable bleeding disorder associated with FXI deficiency, 5 and because monospecific FXI inhibitors have not been widely available for experimental investigation. FXI activation is thought to proceed through thrombinand/or factor XII-dependent mechanisms, and activated FXI (FXIa) contributes to sustained thrombin generation after initiation of blood clotting by activating factor IX.
These activities ultimately promote coagulation, platelet activation, and preservation of fibrin clot integrity. 6, 7 Thrombin also increases the density of fibrin networks, 8 and indirectly inhibits fibrinolysis through activation of carboxypeptidase B (thrombinactivatable fibrinolysis inhibitor, TAFI). 9 Thus, FXI may support thrombus propagation and clot stability by increasing thrombin generation. 10, 11 Compelling circumstantial evidence suggests a contributory role for FXI in the pathogenesis of thrombosis. An elevated plasma FXI level appears to be an independent risk factor for deep vein thrombosis (DVT), 12 ischemic stroke, 13 and myocardial infarction 14 in humans. While one study did not detect a reduced incidence of myocardial infraction in patients with severe factor XI deficiency, 15 the incidence of ischemic stroke appears to be significantly lower in FXI deficiency than in the general
For personal use only. on . by guest www.bloodjournal.org From population. 16 FXI deficiency reduces occlusive thrombus formation in mouse models, 17, 18 and pharmacological inhibition of FXI is antithrombotic in rabbits 19 and primates. 20 Despite these findings, FXI appears to play a supportive role in normal hemostasis, and only a fraction of the individuals with severe factor XI deficiency exhibit a mild to moderated bleeding tendency upon injury. 5, 21 In contrast, hemophilia (factor VIII or IX deficiency) or factor deficiencies in the common pathway of coagulation (factors II, V, or X) are associated with severe bleeding or are incompatible with life. 22, 23 Taken together, these observations suggest that thrombosis and hemostasis, while linked in many respects, possess mechanistic differences that may allow development of more thrombosis-specific anticoagulant strategies such as targeting of FXI.
To investigate the mechanism by which FXI contributes to acute thrombus formation, baboon and flow chamber models were employed. To block FXI activity, a potent monospecific neutralizing antibody was generated. A sensitive model was developed for locally measuring soluble markers of activated coagulation, platelets, and fibrinolysis at sites of experimental thrombus formation in baboons. Platelet and fibrin accumulation during arterial thrombogenesis, and the occlusion of thrombogenic blood conduits were determined in the presence and absence of the antibody.
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Materials and methods

Experimental animals
39 non-terminal studies were performed using 17 male baboons (Papio anubis, 9-11 kg).
All studies were approved by the Institutional Animal Care and Use Committee of Oregon Health and Science University. Thrombosis experiments were conducted on non-anticoagulated awake animals that had chronic exteriorized femoral arteriovenous shunts, as described elsewhere. 24 Baseline shunt blood flow exceeded 250 ml/min in all study animals. Anxiety was managed with low dose ketamine (< 2 mg/kg/hr). Platelet counts, red cell counts, and hematocrits were measured daily, before and after the experiments. Calculated blood loss did not exceed 4% of total blood volume on any experimental day.
Thrombosis model
Thrombus formation was initiated within chronic arteriovenous shunts in baboons by interposing a prosthetic vascular graft segment for up to 60 min, essentially as described. 24 The hypothrombogenic graft (ePTFE, WL Gore & Co., Flagstaff, AZ) 20 was coated with collagen which consistently triggers platelet-dependent thrombus formation.
Twenty mm long graft segments (internal diameters (i.d.) of either 2 or 4 mm) were filled with equine type I collagen (1 mg/ml; Nycomed Arzenmittel, Munich, Germany) for 15 min, and then dried overnight under sterile airflow. The thrombogenic collagen-coated grafts were then incorporated between segments of silicon rubber tubing, deployed into the shunts (Figure 1 ), and exposed to blood flow. The flow rate through the graft was restricted to 100 ml/min (Transonics Systems flow reduction for 60 min. In the 2 mm diameter grafts, flow rates progressively declined due to occlusive thrombus formation. The grafts were removed from the shunts either at 60 min (4 mm i.d. grafts) or when the flow rate fell from 100 ml/min to 20 ml/min (2 mm i.d. grafts), signaling imminent occlusion. The time from initiation of blood flow through the graft until the flow reached 20 ml/min was taken as the occlusion time.
Thrombus formation was assessed in real time during the experiments by quantitative gamma camera imaging of radiolabeled platelet accumulation within the graft segment, and by end-point determinations of radiolabeled fibrinogen/fibrin deposition, as described. 24 Measurements of platelet-associated radioactivity on the grafts were recorded at 5-min (4 mm i.d.) or 3-min (2 mm i.d.) intervals using a GE-400T gamma scintillation camera interfaced with a NuQuest InteCam computer system. Embolic events were recorded as abrupt decreases in the number of platelets in the graft between subsequent imaging frames.
Blood sample collection
Systemic samples were collected proximal to the graft from the midstream of the shunt into 3.8% citrate (1:9, v/v) before graft deployment, and then at 30 and 60 min. One sample was processed for platelet poor plasma and used to assess FXI procoagulant activity levels, while a second sample was used for determination of systemic coagulation markers (vide infra). For the assessment of thrombosis markers generated within the 4 mm i.d. grafts, samples were also taken from the blood stream adjacent to the vessel wall (intraluminal boundary layer) immediately distal to the thrombus. Blood was collected at a rate of 100 µl/min during 10 min intervals through a 0.64 mm i.d. port located 10 mm distal to the graft ( Figure 1 ). To maintain patency of the sampling port, Phe-Pro-Arg-chloromethylketone (PPACK, 0.5 mg/ml, 1 mM), which inhibits thrombin 
Blood sample analysis
Blood cell counts were determined using a micro-60 automated cell counter (Horiba-ABX Diagnostics). Blood samples were divided into aliquots and processed according to specific test requirements. Plasma was prepared from one aliquot and activated partial thromboplastin times (aPTT) and prothrombin times (PT) were measured on site.
Another aliquot was placed on ice for 10 min and centrifuged at 4º C for 10 min at 12,900 g. 
Derivation of neutralizing anti-factor XI antibody
Since previous studies showed that polyclonal antibodies to human FXI required very high doses to achieve near-complete inhibition of FXI in baboons, 20 we generated a new reagent, a potent neutralizing anti-human FXI monoclonal antibody (aXIMab) that crossreacts with baboon FXI. Hybridomas were derived from Balb/c mice immunized with purified human FXI using standard procedures. 26 Hybridomas were screened using solid phase ELISA against human FXI, and those that showed binding were subcloned twice by limiting dilution. The clone that produced the most potent neutralizing antibody, which 
Pharmacological inhibition of FXI and platelet activity in vivo
In a pilot experiment, aXIMab (2 mg/kg) was administered to a single baboon, and blood samples were collected into citrate anticoagulant over 4 weeks to measure circulating FXI antigen (FXI:Ag) concentrations, FXI inhibitor, and FXI procoagulant activity. This dose of aXIMab was chosen with the intent to achieve sustained and near-complete inhibition of FXI, assuming an initial dilution of the antibody into 60 ml blood volume per kg body weight after injection. The maximum achievable prolongation of the aPTT was about 2.5 fold. FXI:Ag was measured by ELISA using goat anti-human FXI polyclonal performed by size fractionation of 1 μl samples of plasma under non-reducing conditions on 7.5% polyacrylamide-SDS gels, followed by transfer to PVDF membranes. Detection was with a goat-anti-human FXI polyclonal antibody conjugated to HRP and chemiluminescence. In the same samples, the Bethesda assay 29 was used to determine excess (non-complexed) circulating FXI inhibitor (aXIMab) activity levels, and the FXI procoagulant activity was measured using a clotting assay. 28 P-selectin (Bender MedSystem, monkey sP-selectin ELISA) and fibrinogen (Clauss assay) levels were measured as global plasma markers for inflammation.
aXIMab was administered as a bolus (2 mg/kg intravenously) at least 24 h before the thrombosis experiments. The anticoagulant effect was monitored daily, and thrombosis experiments were performed while the systemic FXI procoagulant activity was reduced by ≥99%. We previously showed that inhibition of FXI by polyclonal antibodies is safer and as effective as high dose heparin in baboons. 20 Aspirin has less pronounced effects on hemostasis than heparin, and is often used in the treatment of arterial-type platelet dependent thrombosis. The affect of ASA treatment was compared to aXIMab on the occlusion-prone 2 mm i.d. grafts. ASA (32 mg/kg) was administered orally 2 to 4 h before each thrombosis experiment, as described previously. 30 Four weeks were allowed for washout of each aXIMab and ASA before performing new experiments in the same animal.
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Hemostasis assessment
The effects of FXI inhibition and aspirin on hemostasis in baboons were assessed using the standard template skin bleeding time test (Surgicutt ® , International Technidyne Corp). Experimentally, this tests has been shown to be sensitive to the effects of therapeutic anticoagulants and anti-platelet agents in non-human primates. 31, 32 All bleeding time measurements were performed by the same expert technician.
Modeling of thrombosis marker mass transport and local sampling
A 3D computational fluid dynamics model, similar to that presented by Xu et al, 33 was used to estimate the concentrations of thrombus-derived macromolecules in blood that flows over forming thrombus and transports the markers along the adjacent vessel wall distally. The model was based on the geometry shown in Figure 1 , with typical values for blood density and viscosity. 34 The model of local blood sampling was implemented using the finite element software ADINA (Watertown, MA). In addition, a 2D axisymmetric computational model, similar to that of Markou et al, 35 was used to estimate thrombosis marker distribution within the flow field. Computational modeling predicted that molecules of interest (βTG, fibrin D-dimer, and TAT) released or generated at sites of thrombus formation, would be concentrated (>99%) within a very thin peripheral blood boundary layer (~0.1 mm thick concentration boundary layer) along the immediately distal vessel wall (data not shown). Thus, as employed here, the local sampling method effectively sampled the entire near-wall concentration boundary layer region, immediately distal to the forming thrombus, for platelet and coagulation markers of interest.
Flow chamber coagulation studies
Glass capillary tubes coated with 100 µg/ml Horm collagen (Nycomed Arzenmittel, Munich, Germany) were used as thrombus chambers. Whole human blood was collected into corn trypsin inhibitor (CTI, 40 µg/ml), discarding the first 1 ml to limit activation of coagulation. The blood was perfused through the thrombus chambers at a shear rate of 265 s -1 for 10 min. Prior to each experiment, blood was incubated with aXIMab (20 µg/ml), heparin (15 U/ml), a combination of an inhibitory anti-TF antibody (20 µg/ml, Genentech) and FVIIai (1 µg/ml, NovoNordisk), and/or PBS vehicle (all concentrations final). In separate experiments, washed platelets and RBCs were processed as described, 36 and then mixed with FXII deficient human plasma (<1% FXII, Haematologic Technologies) to reach a hematocrit of 40% and platelet count of 300 x10 3 /µl. The reconstituted blood was incubated with aXIMab (20µg/ml) or CTI (40µg/ml), recalcified with 7.5mM CaCl 2 and 3.75mM MgCl 2 , and then perfused immediately through collagen coated capillary tubes. Recalcified FXII deficient human plasma without RBCs or platelets was also perfused over collagen. Images were obtained by DIC microscopy after three minutes of perfusion with modified Tyrodes buffer to wash out unbound blood components.
Data analysis
Mean values are given ± 1 SEM (standard error of the mean). Occlusion data were compared using the log-rank test. 
Results
Inhibition of FXI by aXIMab ex vivo prevents fibrin formation independent of FXIIa
When CTI-anticoagulated fresh whole human blood was perfused over collagen at arterial shear (265 s -1 ), platelets were deposited in large aggregates which became enveloped by forming fibrin strands ( Figure 2B ). In stark contrast, when CTI blood was further anticoagulated with either heparin or aXIMab, fibrin deposition was greatly reduced. In these short experiments, there was no obvious reduction in platelet adhesion to collagen by the anticoagulants. The outcome was similar when using reconstituted FXII deficient blood, with or without CTI. Fibrin was generated independent of FXII, and 
Inhibition of FXI with aXIMab, in vivo
A baboon given aXIMab (2mg/kg) was followed for 4 weeks post-injection to assess FXI antigen (FXI:Ag), anticoagulant activity, and antibody inhibitor levels. FXI:Ag levels (complexed and native) decreased from 110% to 40% of NBP levels by 60 min, but steadily increased thereafter, reaching 300% of control by day 8 post treatment ( Figure   3A ). FXI:Ag remained above 200% of control through day 15, after which there was a
13
decrease to 130% by day 27. FXI activity decreased from 125% to <1% at 1 h after aXIMab administration, and remained inhibited by >99% for 10 days after administration.
FXI activity gradually increased to 136% by day 27. Maximum circulating FXI inhibitor levels were observed at 1 h post aXIMab infusion (72 Bethesda units [BU]), which decreased to 0.6 BU by day 13, and were undetectable thereafter ( Figure 3B ).
Consistent with the FXI:Ag ELISA data, the 160 kDa band representing the FXI homodimer on SDS PAGE and Western blots of plasma increased in intensity between day 0 and 8 ( Figure 3C ). These results indicate that the anticoagulant effect of aXIMab was due to its sustained presence in the circulation, and its ability to block FXI activation and/or activity, and not to clearance of the zymogen from the circulation. Since aXIMab separates from FXI during SDS gel electrophoresis, it remains unclear whether inhibition of FXI by aXIMab caused a rebound increase in FXI secretion or the FXI-aXIMab immune complexes were cleared slowly from the circulation. In the same samples, Pselectin and fibrinogen levels were determined as indirect measures for inflammation, with no remarkable changes from baseline detected (data not shown).
In thrombosis studies using aXIMab, FXI procoagulant activity was inhibited by 99.0% (98. .5%) at 1 h after injection and remained inhibited by 99% in all animals for at least 7 days. No observable adverse events were associated with the treatment. aPTT values were prolonged after aXIMab administration to 65.6 ± 2.0 sec compared with 30.5 ± 0.7 sec in control animals, while the PT values remained comparable to baseline (9.1 ± 0.1 vs. 9.0 ± 0.1 sec, respectively, n = 11 for each). Platelet aggregation in platelet rich plasma in response to adenosine diphosphate (ADP) and collagen was not affected by aXIMab-treatment (data not shown).
Protection of aXIMab-treated baboons from collagen-initiated thrombus development
Administration of aXIMab reduced platelet and fibrin deposition in the 4 mm i.d. collagencoated vascular grafts. Significant differences in platelet accumulation between aXIMaband vehicle-treated groups were seen as early as 10 min after graft exposure to blood flow (0.13 ± 0.03 x 10 9 versus 0.23 ± 0.03 x 10 9 platelets, aXIMab versus vehicle control, P < 0.05). The differences remained statistically significant throughout the time course of thrombus propagation ( Figure 4A ). Graft platelet accumulation at 60 min was 63% lower in aXIMab-treated animals than in vehicle controls (1.38 ± 0.26 x 10 9 versus 3.68 ± 0.52 x 10 9 platelets, aXIMab versus control, n = 6 and 8, respectively, P < 0.01; Figure 4A ).
Systemic platelet counts were similar in aXIMab (341 ± 27 x 10 3 /µl) and control groups (337± 31 x 10 3 /µl), and did not change significantly following thrombosis experiments.
End-point fibrin deposition was reduced by 81% compared with controls (0.23 ± 0.07 mg and 1.18 ± 0.19 mg, aXIMab versus control, P = 0.001; Figure 4B ). Since aXIMab is monospecific for the A3 domain of FXI, these data verify that FXI plays an important role in thrombus propagation under arterial-type flow conditions in primates.
Reduced thrombin generation and platelet activation in aXIMab-treated baboons
Since inhibition of FXI could reduce thrombus formation in vivo both by limiting thrombin- Figure 5A ). TAT levels in plasmas obtained by local sampling were lower, by up to 98% at 40 min, while systemic TAT levels were 81% lower at 60 min compared with the untreated controls (4.3 ± 0.5 versus 22.1 ± 2.5 µg/L, n = 6 and 7, respectively, P < 0.001; Figure 5B ). Since thrombin does not interact with antithrombin in the presence of PPACK, all TAT in the sample was likely generated before the blood entered the sampling port. Thus, while reflecting thrombin generation, TAT levels are likely an underestimation of the total thrombin. Platelet activation at the thrombus surface, as assessed by the release of platelet α -granule β TG, was 86% lower at 30 min in samples taken distal to thrombi in aXIMab-treated animals compared with vehicle-treated controls ( Figure 5C ). Systemic β TG levels in aXIMab-treated animals measured at 60 min were 42% less (23.0 ± 2.1 IU/ml, n = 6) compared with vehicle-treated controls (39.5 ± 5.5 IU/ml, n = 7; Figure 5D , P < 0.05). Local D-dimer levels were not changed at 60 min compared with baseline systemic values in either control (2.3 ± 0.2 and 2.4 ± 0.4 µg/ml, respectively, n = 7) or aXIMab-treated animals (2.4 ± 0.2 and 2.2 ± 0.2 µg/ml, respectively n = 6; Figure 5E ). Systemic D-dimer levels assessed at 60 min also were unchanged from baseline systemic values in both groups (2.4 ± 0.3 and 2.3 ± 0.2 µg/ml, control versus aXIMab-treated animals). This confirms previous reports from similar baboon studies showing systemic D-dimer levels do not increase by 60 min after thrombus initiation, unless a thrombolytic agent is administered. 37, 38 These data indicate that: 1) FXI plays an important role in thrombin generation and platelet activation during acute, arterial-type thrombus formation, and 2) endogenous local thrombolysis appears to be limited during the time course of these studies, regardless of FXI activity. grafts occluded by 27.0 ± 3.3 min (P < 0.01; Figure 6 and Table 1 ). Fibrin accumulation was also reduced by aXIMab treatment versus the vehicle-treated controls (0.18 ± 0.02 versus 0.30 ± 0.04 mg, respectively, P < 0.01; Table 1 ). As expected, treatment with high dose ASA reduced platelet deposition in the 2 mm i.d. grafts, but did not completely interrupt occlusive thrombus formation. The time to graft occlusion was prolonged by aspirin by an average of 18 min in 4 grafts, while 2 additional grafts remained patent throughout the 60 min study interval. High dose ASA was therefore less effective in preventing graft occlusion than aXIMab (P < 0.05, aXIMab versus ASA). These data indicate that FXI plays an important role in the thrombogenic process that leads to acute occlusion of small caliber vascular grafts.
Treatment with aXIMab does not prolong the bleeding time in baboons
The template bleeding time is typically prolonged by both anti-platelet agents and anticoagulants in baboons, 31 ,39 yet FXI inhibition by aXIMab had no effect on the 
Discussion
The present findings document that FXI is an essential contributor to local thrombin generation on the surface of thrombi during arterial-type thrombogenesis. FXI inhibition in baboons slowed platelet accumulation onto a thrombogenic surface (collagen-coated vascular grafts) under moderate arterial shear conditions (Figure 4) . While FXI inhibition did not demonstrably affect platelet adhesion to collagen in the ex vivo chamber perfusion studies, it clearly reduced centripetal accumulation of platelet aggregates over longer periods of time in the 2 mm i.d. grafts. The stability of thrombi formed under higher shear flow was noticeably dependent on FXI activity (Table 1 and Figure 6 ).
Indeed, under high shear, repeated loss of platelets from the graft was distinctly evident in aXIMab-treated animals, a mechanism which likely contributed to preventing graft occlusion. These findings are consistent with the antithrombotic and anti-occlusive phenotype observed in FXI deficient mice following ferric chloride-induced arterial injury and thrombosis. 17, 18, 40 FXI promotes clot resistance to fibrinolysis through thrombin-mediated activation of the metalloproteinase TAFI, which proteolytically modifies fibrin making it resistant to plasmin. 41, 42 In addition, inhibition of thrombin generation by anticoagulants enhances clot lysis due to a slower forming, less dense fibrin network. 43, 44 Both processes may account, at least in part, for the enhanced lysis of blood clots formed in the presence of an anticoagulant anti-factor XI antibody in the clamped jugular vein of rabbits. 11 During the present studies in baboons, the fibrin degradation product D-dimer was measured by local blood sampling in the vicinity of fibrin-, platelet-, and leukocyte-rich arterial-type thrombi. Unlike the robust changes in TAT and β TG levels, there were no changes in local D-dimer levels in vehicle-or aXIMab-treated baboons. This finding suggests that
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From endogenous fibrinolysis may not be a dominant process on the surface of thrombi during acute arterial thrombogenesis, which is consistent with the observation that TAFI deficient mice that were expected to have a fibrinolytic phenotype were not protected against injury-induced arterial thrombus formation. 45 Since adjacent endothelial cells capable of secreting tPA are absent from the graft, the data do not rule out the possibility of reduced TAFI activity and more efficient fibrinolysis during inhibition of FXI. Our data suggests however that the relative reduction in deposited fibrin associated with FXI inhibition was not caused by an increase in fibrinolysis.
The inhibitory effect of aXIMab on thrombogenesis and TAT formation suggests that sustained thrombus propagation on the luminal flow surface depends on FXI-mediated thrombin generation. FXI-dependent thrombin generation could occur via continued FXI activation by FXIIa, thrombin, and/or autoactivation. 7, 46 FXIIa appears to play an important role in experimental thrombosis in mice. 47 However, the flow chamber data While FXI activity decreased to <1% for over a week following aXIMab injection, total FXI:Ag levels temporarily increased several-fold above baseline following the disappearance of FXI activity in the baboon circulation. Whether this increase was due Significance levels are **P < 0.01, ***P = 0.001, by the two-tailed Student's t-test. Values are means ± SEM. graft segments were placed in permanent arteriovenous shunts in untreated (n=9), ASA treated (n=6), and aXIMab treated (n=5) animals. Blood was allowed to flow through the grafts at a rate of 100 ml/min, producing an average initial wall shear rate of 2120 s -1 .
The flow was maintained by the pulsatile arterial pressure until the graft occluded (defined as ≤ 20 ml/min flow rate). Thrombi that formed in the grafts in the aXIMab treated animals were unstable, embolized more frequently than in ASA-treated animals,
